These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 15205096

  • 1. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
    Kattamis A, Lagona E, Orfanou I, Psichou F, Ladis V, Kanavakis E, Metaxotou-Mavrommati A, Kattamis C.
    Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
    [Abstract] [Full Text] [Related]

  • 2. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, Castro O, Barton F.
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [Abstract] [Full Text] [Related]

  • 3. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Feb; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK, McCarthy WF, Guo N, Brugnara C, Kling G, Bauserman RL, Waclawiw MA.
    Hemoglobin; 2010 Jul; 34(5):424-9. PubMed ID: 20854115
    [Abstract] [Full Text] [Related]

  • 9. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
    Mellouli F, Bejaoui M.
    Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
    [Abstract] [Full Text] [Related]

  • 10. Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.
    Adekile AD.
    Hemoglobin; 2011 Jan; 35(5-6):607-17. PubMed ID: 21999156
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
    Moschovi M, Psychou F, Menegas D, Tsangaris GT, Tzortzatou-Stathopoulou F, Nicolaidou P.
    Pediatr Hematol Oncol; 2001 Sep; 18(6):371-6. PubMed ID: 11554231
    [Abstract] [Full Text] [Related]

  • 13. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A, Gumruk F, Gurgey A.
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [Abstract] [Full Text] [Related]

  • 14. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
    Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A.
    Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
    [Abstract] [Full Text] [Related]

  • 16. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
    Conran N, Fattori A, Saad ST, Costa FF.
    Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
    [Abstract] [Full Text] [Related]

  • 17. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
    Vasavda N, Badiger S, Rees D, Height S, Howard J, Thein SL.
    Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
    [Abstract] [Full Text] [Related]

  • 18. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K, Smith-Whitley K.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [Abstract] [Full Text] [Related]

  • 19. [Hydroxyurea, erythrocyte volumes and hemoglobin F].
    Bargetzi MJ, Schönenberger A, Tichelli A, Passweg J, Rabaglio M, Singer D, Sissolak G, Gratwohl A, Speck B.
    Schweiz Med Wochenschr; 1995 Mar 04; 125(9):433-5. PubMed ID: 7534433
    [Abstract] [Full Text] [Related]

  • 20. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P.
    Ann Hematol; 2004 Jul 04; 83(7):430-3. PubMed ID: 14722738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.